Skip to main content

Table 2 Primary graft dysfunction development in both groups in four tracked time periods. Data are presented as n (%)

From: Effect of targeted coagulopathy management and 5% albumin as volume replacement therapy during lung transplantation on allograft function: a secondary analysis of a randomized clinical trial

Time 0

PGD grade

0

1

2

3

p-value

non-POC

16 (44.4)

6 (16.7)

6 (16.7)

8 (22.2)

0.048

POC

22 (70.9)

2 (6.5)

6 (19.4)

1 (3.2)

Time 24

PGD grade

0

1

2

3

p-value

non-POC

13 (36.1)

15 (41.7)

4 (11.1)

4 (11.1)

0.08

POC

21 (67.7)

7 (22.6)

2 (6.5)

1 (3.2)

Time 48

PGD grade

0

1

2

3

p-value

non-POC

13 (36.1)

14 (38.9)

9 (25)

0

0.052

POC

20 (64.5)

6 (19.4)

4 (12.9)

1 (3.2)

Time 72

PGD grade

0

1

2

3

p-value

non-POC

16 (44.4)

11 (30.6)

8 (22.2)

1 (2.8)

0.003

POC

25 (80.7)

5 (16.1)

0

1 (3.2)

  1. Abbreviations: PGD primary graft dysfunction, POC point of care